此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

MAM01 在健康成人中的安全性、耐受性、药代动力学和保护功效

2026年5月18日 更新者:Gates Medical Research Institute

一项针对受控人类疟疾感染 (CHMI) 的剂量递增、双盲、安慰剂对照临床试验,旨在评估抗疟疾人类单克隆抗体 MAM01 在未感染疟疾的健康人中的安全性、耐受性、药代动力学和保护功效成年人

这是针对恶性疟原虫 (Pf) 环子孢子蛋白 (CSP) 的 MAM01 单克隆抗体 (mAb) 的首次人体 (FiH) 双盲、随机、安慰剂对照、两部分剂量递增试验。 本研究将评估 MAM01 的安全性、耐受性、药代动力学 (PK) 和保护功效,以及重复皮下 (SC) 给药的安全性和 PK。

研究概览

研究类型

介入性

注册 (实际的)

63

阶段

  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Maryland
      • Baltimore、Maryland、美国、21201
        • Center for Vaccine Development and Global Health, 685 W. Baltimore Street

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 成人

接受健康志愿者

是的

描述

纳入标准:

  • 通过医学评估(包括病史、体格检查和实验室检查)确定健康的参与者。
  • 身体质量指数 (BMI) 18 至 30 公斤每平方米 (kg/m^2)(含)至最大 220 磅。
  • 根据以下条件,男性和女性都有资格参加:

    A。女性参与者身体上有怀孕能力,在筛选期间、入组当天、研究产品 (IP) 给药前、CHM 前和抗疟治疗开始时至少有一次妊娠试验阴性,并且同意使用有效的避孕措施从入组前 28 天到完成试验访视避免怀孕。

  • 能够签署知情同意书,包括遵守知情同意书 (ICF) 和本协议中列出的要求和限制,并完成理解测试(如果他/她可以参与 CHMI 程序)。
  • 已报告已完成原发性冠状病毒病 (COVID) 疫苗系列。

排除标准:

  • 服药当天出现急性疾病或发烧≥99.5°华氏度 (F)(或 >37.5 摄氏度)。
  • 怀孕或哺乳的妇女。
  • 研究者判断的具有临床意义的医学病症的证据和/或病史,包括恶性肿瘤、糖尿病和不稳定或不受控制的高血压。
  • 使用 Gaziano 列线图得出的 5 年心血管风险 >10%。
  • 任何自身免疫性疾病或免疫缺陷或其他免疫系统损伤的病史,包括但不限于人类免疫缺陷病毒 (HIV)、自身免疫性疾病或免疫抑制治疗。
  • 在第 1 天试验药物给药前 180 天内参加介入性临床试验和/或接受任何研究药物。
  • 预期使用已知会引起与氯喹或 atovaquoneproguanil (Malarone) 药物反应的药物,例如西咪替丁、甲氧氯普胺、抗酸剂和高岭土。

注意:其他协议定义的包含/排除标准可能适用。

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:预防
  • 分配:随机化
  • 介入模型:顺序分配
  • 屏蔽:双倍的

武器和干预

参与者组/臂
干预/治疗
实验性的:A 部分:单剂量递增 (SAD):剂量递增队列 1:MAM01 和安慰剂静脉注射 (IV)
2 名哨兵参与者将以 1:1 的比例随机接受 MAM01 1.5 毫克/千克 (mg/kg) IV 或安慰剂。 在至少 24 小时的安全审查期之后,队列 1 的其余 6 名参与者将以 5:1 的比例随机分配接受 MAM01 1.5 mg/kg IV 或安慰剂。
1.5 mg/kg MAM01 将通过 IV 途径给药。
安慰剂将通过静脉注射途径给药。
安慰剂将通过 SC 途径给药。
实验性的:A 部分:SAD 给药:剂量递增队列 2:MAM01 和安慰剂 SC
7 名参与者将以 6:1 的比例随机分配接受 MAM01 5 mg/kg SC 或安慰剂
安慰剂将通过静脉注射途径给药。
安慰剂将通过 SC 途径给药。
5 mg/kg MAM01 将通过 SC 途径施用。
5 mg/kg MAM01 将通过 IV 途径给药。
实验性的:A 部分:SAD 给药:剂量递增队列 3:MAM01 和安慰剂 IV
7 名参与者将以 6:1 的比例随机分配接受 MAM01 5 mg/kg IV 或安慰剂。
安慰剂将通过静脉注射途径给药。
安慰剂将通过 SC 途径给药。
5 mg/kg MAM01 将通过 SC 途径施用。
5 mg/kg MAM01 将通过 IV 途径给药。
实验性的:A 部分:SAD 给药:剂量递增队列 4:MAM01 和安慰剂 IV
8 名参与者将以 6:2 的比例随机分配接受 MAM01 10 mg/kg IV 或安慰剂。
安慰剂将通过静脉注射途径给药。
安慰剂将通过 SC 途径给药。
10 mg/kg MAM01 将通过 IV 途径给药。
实验性的:A 部分:SAD 给药:剂量递增队列 5:MAM01 和安慰剂 IV
7 名参与者将以 6:1 的比例随机分配接受 MAM01 40 mg/kg IV 或安慰剂
安慰剂将通过静脉注射途径给药。
安慰剂将通过 SC 途径给药。
40 mg/kg MAM01 将通过 IV 途径给药。
实验性的:A 部分:多次递增剂量 (MAD)(重复给药):MAM01
来自群组 2 和群组 3 的参与者将接受 5 mg/kg MAM01 SC。
5 mg/kg MAM01 将通过 SC 途径施用。
5 mg/kg MAM01 将通过 IV 途径给药。
实验性的:B 部分:剂量扩展队列 6:第 1 组:MAM01
6 名参与者将接受 450 毫克 SC 剂量的 MAM01。 通过应用 A 部分数据中的 PK 药效 (PD) 模型来选择剂量,以估计受控人类疟疾感染 (CHMI) 的(数据驱动的)保护阈值。
MAM01 将通过 SC 途径进行管理。
实验性的:B 部分:剂量扩展队列 6:第 2 组:MAM01
8 名参与者将接受 600 毫克 SC 剂量的 MAM01。 通过应用 A 部分数据中的 PK-PD 模型来选择剂量,以估计 CHMI 的(数据驱动的)保护阈值
MAM01 将通过 SC 途径进行管理。
实验性的:B 部分:剂量扩展队列 6:第 3 组:MAM01
8 名参与者将接受 900 毫克 SC 剂量的 MAM01。 通过应用 A 部分数据中的 PK-PD 模型来估计 CHMI 的(数据驱动的)保护阈值来选择剂量。
MAM01 将通过 SC 途径进行管理。
实验性的:内部传染性控制
6 名参与者将在 CHMI 之前被纳入非随机组。 这些参与者将不会接受任何治疗并充当感染控制者
不会使用任何药物或安慰剂。

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Number of Participants Reporting Solicited Adverse Events (AEs) in the Subcutaneous Cohorts
大体时间:Day 1 to Day 7 post dose
Solicited AEs were defined events participants were specifically asked about, which were recorded by participants in the memory aid card. Solicited AES included local injection site AEs (pain, redness, swelling, itching and bruising) and systemic AEs (fever, chills, headache, fatigue, nausea, muscle pain and joint pain). A Solicited AE does not necessarily have a causal relationship with the intervention.
Day 1 to Day 7 post dose
Number of Participants Reporting Unsolicited Adverse Events
大体时间:Through Day 28 post dose
In this study an unsolicited AE is any AE not captured as a solicited AE in the Memory Aid Card between Day 0 and Day 7 after MAM01 dosing, and all AEs occurring after Day 7 post dose were collected as Unsolicited AEs.
Through Day 28 post dose
Number of Participants Reporting Serious Adverse Events (SAEs) Including Suspected Unexpected Serious Adverse Reactions (SUSARs) and Adverse Events Special Interest (AESIs)
大体时间:Up to Day 168
A SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect or is a medically significant / important event or reaction. SUSARs are AEs reported for a clinical trial participant, which is assessed by the Sponsor and or study investigator as being unexpected, serious and as having a reasonable possibility of a causal relationship with the study drug. AESIs are adverse events that the Sponsor wants to monitor closely and which require expedited reporting.
Up to Day 168
Number of Participants Who Received 2 Doses Reporting SUSARs, SAEs and AESIs
大体时间:Through Day 336
A SAE is defined as any untoward medical occurrence that, at any dose: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect or is a medically significant / important event or reaction. SUSARs are AEs reported for a clinical trial participant, which is assessed by the Sponsor and or study investigator as being unexpected, serious and as having a reasonable possibility of a causal relationship with the study drug. AESIs are adverse events that the Sponsor wants to monitor closely and which require expedited reporting.
Through Day 336
Number of Participants With Clinically Significant Changes in Serum Chemistry Parameters
大体时间:Through Day 336
Blood samples were collected for the assessment of alanine transaminase, aspartate aminotransferase, alkaline phosphatase, total carbon-dioxide (CO2), chloride, total bilirubin, creatinine, blood urea nitrogen, glucose, albumin, total protein, sodium and potassium.
Through Day 336
Number of Participants With Clinically Significant Changes in Hematology Parameters
大体时间:Through Day 336
Blood samples were collected for the assessment of complete blood count (CBC) including hemoglobin, platelet count, and white blood cell counts, and differential to include the absolute counts for neutrophils, lymphocytes, eosinophils, and monocytes.
Through Day 336

次要结果测量

结果测量
措施说明
大体时间
Maximal Observed Concentration (Cmax) Following Single Dose of MAM01
大体时间:Pre-dose, Day 0: end of infusion (EOI), 1, 3 and 6 hours; Day 1: 24 hours; Day 2: 48 hours; Days 7, 14, 28, 42, 56, 70, 84, 98, 112, 140, 168, 224 and 280 post-dose
Serum from venous blood samples was collected for measurement of MAM01 pharmacokinetics.
Pre-dose, Day 0: end of infusion (EOI), 1, 3 and 6 hours; Day 1: 24 hours; Day 2: 48 hours; Days 7, 14, 28, 42, 56, 70, 84, 98, 112, 140, 168, 224 and 280 post-dose
Cmax Following Repeat Dosing of MAM01
大体时间:Pre-dose, Day 0: end of infusion (EOI), 1, 3 and 6 hours, Day 1: 24 hours, Day 2: 48 hours, Days 7, 14, 28, 42, 56, 70, 84, 98, 112, 140, 168, 224 and 280 post-dose
Serum from venous blood samples was collected for measurement of MAM01 pharmacokinetics.
Pre-dose, Day 0: end of infusion (EOI), 1, 3 and 6 hours, Day 1: 24 hours, Day 2: 48 hours, Days 7, 14, 28, 42, 56, 70, 84, 98, 112, 140, 168, 224 and 280 post-dose
Area Under the Curve (AUC) From Time=0 to the Last Measurable Concentration (AUC0-t) Following Single Dose of MAM01
大体时间:Pre-dose, Day 0: end of infusion (EOI), 1, 3 and 6 hours; Day 1: 24 hours; Day 2: 48 hours; Days 7, 14, 28, 42, 56, 70, 84, 98, 112, 140, 168, 224 and 280 post-dose
Serum from venous blood samples was collected for measurement of MAM01 pharmacokinetics.
Pre-dose, Day 0: end of infusion (EOI), 1, 3 and 6 hours; Day 1: 24 hours; Day 2: 48 hours; Days 7, 14, 28, 42, 56, 70, 84, 98, 112, 140, 168, 224 and 280 post-dose
AUC (0-t) Following Repeat Dosing of MAM01
大体时间:Pre-dose, Day 0: end of infusion (EOI), 1, 3 and 6 hours; Day 1: 24 hours; Day 2: 48 hours; Days 7, 14, 28, 42, 56, 70, 84, 98, 112, 140, 168, 224 and 280 post-dose
Serum from venous blood samples was collected for measurement of MAM01 pharmacokinetics.
Pre-dose, Day 0: end of infusion (EOI), 1, 3 and 6 hours; Day 1: 24 hours; Day 2: 48 hours; Days 7, 14, 28, 42, 56, 70, 84, 98, 112, 140, 168, 224 and 280 post-dose
Partial AUC's Time= 0 to the CHMI Challenge (AUC0-CHMI) of MAM01
大体时间:Pre-dose, Day 0: end of infusion (EOI), 1, 3 and 6 hours; Day 1: 24 hours; Day 2: 48 hours; Days 7, 14, 28, 42, 56, 70, 84, 98, 112, 140, 168, 224 and 280 post-dose
Serum from venous blood samples was collected for measurement of MAM01 pharmacokinetics.
Pre-dose, Day 0: end of infusion (EOI), 1, 3 and 6 hours; Day 1: 24 hours; Day 2: 48 hours; Days 7, 14, 28, 42, 56, 70, 84, 98, 112, 140, 168, 224 and 280 post-dose
Concentration at the Time of CHMI (CCHMI) of MAM01
大体时间:Pre-dose, Day 0: end of infusion (EOI), 1, 3 and 6 hours; Day 1: 24 hours; Day 2: 48 hours; Days 7, 14, 28, 42, 56, 70, 84, 98, 112, 140, 168, 224 and 280 post-dose
Serum from venous blood samples was collected for measurement of MAM01 pharmacokinetics.
Pre-dose, Day 0: end of infusion (EOI), 1, 3 and 6 hours; Day 1: 24 hours; Day 2: 48 hours; Days 7, 14, 28, 42, 56, 70, 84, 98, 112, 140, 168, 224 and 280 post-dose
Blood Terminal Elimination Rate Constant (λz) of MAM01
大体时间:Pre-dose, Day 0: end of infusion (EOI), 1, 3 and 6 hours; Day 1: 24 hours; Day 2: 48 hours; Days 7, 14, 28, 42, 56, 70, 84, 98, 112, 140, 168, 224 and 280 post-dose
Serum from venous blood samples was collected for measurement of MAM01 pharmacokinetics.
Pre-dose, Day 0: end of infusion (EOI), 1, 3 and 6 hours; Day 1: 24 hours; Day 2: 48 hours; Days 7, 14, 28, 42, 56, 70, 84, 98, 112, 140, 168, 224 and 280 post-dose
Terminal Half Life (t1/2) Following Single Dose of MAM01
大体时间:Time Frame: Pre-dose, Day 0: end of infusion (EOI), 1, 3 and 6 hours; Day 1: 24 hours; Day 2: 48 hours; Days 7, 14, 28, 42, 56, 70, 84, 98, 112, 140, 168, 224 and 280 post-dose
Serum from venous blood samples was collected for measurement of MAM01 pharmacokinetics.
Time Frame: Pre-dose, Day 0: end of infusion (EOI), 1, 3 and 6 hours; Day 1: 24 hours; Day 2: 48 hours; Days 7, 14, 28, 42, 56, 70, 84, 98, 112, 140, 168, 224 and 280 post-dose
t1/2 Following Repeat Dosing of MAM01
大体时间:Pre-dose, Day 0: end of infusion (EOI), 1, 3 and 6 hours; Day 1: 24 hours; Day 2: 48 hours; Days 7, 14, 28, 42, 56, 70, 84, 98, 112, 140, 168, 224 and 280 post-dose
Serum from venous blood samples was collected for measurement of MAM01 pharmacokinetics.
Pre-dose, Day 0: end of infusion (EOI), 1, 3 and 6 hours; Day 1: 24 hours; Day 2: 48 hours; Days 7, 14, 28, 42, 56, 70, 84, 98, 112, 140, 168, 224 and 280 post-dose
AUC From Time=0 Extrapolated to Infinity (AUC0-infinity) of MAM01
大体时间:Pre-dose, Day 0: end of infusion (EOI), 1, 3 and 6 hours; Day 1: 24 hours; Day 2: 48 hours; Days 7, 14, 28, 42, 56, 70, 84, 98, 112, 140, 168, 224 and 280 post-dose
Serum from venous blood samples was collected for measurement of MAM01 pharmacokinetics.
Pre-dose, Day 0: end of infusion (EOI), 1, 3 and 6 hours; Day 1: 24 hours; Day 2: 48 hours; Days 7, 14, 28, 42, 56, 70, 84, 98, 112, 140, 168, 224 and 280 post-dose
Absolute Bioavailability of SC Formulation Following Repeated Dosing of MAM01
大体时间:Pre-dose, Day 0: end of infusion (EOI), 1, 3 and 6 hours; Day 1: 24 hours; Day 2: 48 hours; Days 7, 14, 28, 42, 56, 70, 84, 98, 112, 140, 168, 224, 280 and 378 post-dose
Serum from venous blood samples was collected for measurement of MAM01 pharmacokinetics.
Pre-dose, Day 0: end of infusion (EOI), 1, 3 and 6 hours; Day 1: 24 hours; Day 2: 48 hours; Days 7, 14, 28, 42, 56, 70, 84, 98, 112, 140, 168, 224, 280 and 378 post-dose
Accumulation Ratio (AUC0-168) Following Repeated Doses of MAM01
大体时间:Pre-dose, Day 0: end of infusion (EOI), 1, 3 and 6 hours; Day 1: 24 hours; Day 2: 48 hours; Days 7, 14, 28, 42, 56, 70, 84, 98, 112, 140 and 168 post-dose
Serum from venous blood samples was collected for measurement of MAM01 pharmacokinetics. The accumulation ratio was calculated as the ratio of AUC (0-168) (post first dose) to AUC (210-378) (post redose).
Pre-dose, Day 0: end of infusion (EOI), 1, 3 and 6 hours; Day 1: 24 hours; Day 2: 48 hours; Days 7, 14, 28, 42, 56, 70, 84, 98, 112, 140 and 168 post-dose
Number of Participants With Confirmed Pf Infection Assessed by Quantitative Polymerase Chain Reaction Assay (qRT-PCR) After CHMI
大体时间:Up to Day 27 post-CHMI
The characterization of protective efficacy against Pf following CHMI challenge, was assessed by evaluating the presence or absence of Pf infection as determined by qRT-PCR after CHMI (planned through 4 weeks post-CHMI) and evaluating the time to parasitemia after CHMI in each cohort.
Up to Day 27 post-CHMI
Time to Parasitemia After CHMI
大体时间:Up to Day 27 post-CHMI
Parasitemia was assessed by qRT-PCR up to Day 27 following CHMI. In addition, a thick blood smear was prepared for microscopic analysis, which was examined only once the first qRT-PCR sample tested positive. Daily parasitemia monitoring continued until the participant had a confirmed initial positive qRT-PCR. The first positive qRT-PCR triggered either a second PCR test or microscopic analysis of the blood smear. Once two positive results were obtained, rescue therapy was initiated.
Up to Day 27 post-CHMI
Cohorts 1, 4 and 5: Numbers of Participants With Seroconversion
大体时间:Up to Day 280
The formation of ADAs (immunogenicity) following MAM01 SC and/or IV administration) was evaluated by measuring titers of ADA to MAM01 to last study visit for all participants. Capillary blood samples and selected serum samples were collected on volumetric absorptive micro-sampling (VAMS) devices at timepoints.
Up to Day 280
Cohorts 2 and 3: Numbers of Participants Receiving 2 Doses With Seroconversion
大体时间:Up to Day 378
The formation of ADAs (immunogenicity) following MAM01 SC and/or IV administration) was evaluated by measuring titers of ADA to MAM01 to last study visit for all participants. Capillary blood samples and selected serum samples were collected on volumetric absorptive micro-sampling (VAMS) devices at timepoints.
Up to Day 378
Cohort 6: Numbers of Participants With Seroconversion
大体时间:Up to Day 84
The formation of ADAs (immunogenicity) following MAM01 SC and/or IV administration) was evaluated by measuring titers of ADA to MAM01 to last study visit for all participants. Capillary blood samples and selected serum samples were collected on volumetric absorptive micro-sampling (VAMS) devices at timepoints.
Up to Day 84

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 研究主任:+1 866 789 5767、Gates Medical Research Institute

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2023年8月14日

初级完成 (实际的)

2024年12月13日

研究完成 (实际的)

2024年12月13日

研究注册日期

首次提交

2023年5月26日

首先提交符合 QC 标准的

2023年5月26日

首次发布 (实际的)

2023年6月6日

研究记录更新

最后更新发布 (实际的)

2026年6月12日

上次提交的符合 QC 标准的更新

2026年5月18日

最后验证

2026年5月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

在美国制造并从美国出口的产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅